Literature DB >> 33913087

Vancomycin dosing and therapeutic drug monitoring practices: guidelines versus real-life.

Tatjana Van Der Heggen1,2,3, Franky M Buyle4, Barbara Claus4,5, Annemie Somers4, Petra Schelstraete6, Peter De Paepe7, Sophie Vanhaesebrouck6, Pieter A J G De Cock7,4.   

Abstract

Background Correct dosing and therapeutic drug monitoring (TDM) practices are essential when aiming for optimal vancomycin treatment. Objective To assess target attainment after initial dosing and dose adjustments, and to determine compliance to dosing and TDM guidelines. Setting Tertiary care university hospital in Belgium. Method A chart review was performed in 150 patients, ranging from preterm infants to adults, treated intravenously with vancomycin. Patient characteristics, dosing and TDM data were compared to evidence-based hospital guidelines. Main outcome measures Target attainment of vancomycin after initial dosing and dose adjustments. Results Subtherapeutic concentrations were measured in 68% of adults, in 76% of children and in 52% of neonates after treatment initiation. Multiple dose adaptations (median 2, Q1 1-Q3 2) were required for target attainment, whilst more than 20% of children and neonates never reached targeted concentrations. Regarding compliance to the hospital guideline, some points of improvement were identified: omitted dose adjustment in adults with decreased renal function (53%), delayed sampling (16% in adults, 31% in children) and redundant sampling (34% of all samples in adults, 12% in children, 13% in neonates). Conclusion Target attainment for vancomycin with current dosing regimens and TDM is poor in all age groups. Besides, human factors should not be ignored when aiming for optimal treatment. This study reflects an ongoing challenge in clinical practice and highlights the need for optimization of vancomycin dosing strategies and improvement of awareness of all health care professionals involved.

Entities:  

Keywords:  Antibiotic dosing; Belgium; Dosing errors; Therapeutic drug monitoring; Vancomycin

Year:  2021        PMID: 33913087     DOI: 10.1007/s11096-021-01266-7

Source DB:  PubMed          Journal:  Int J Clin Pharm


  58 in total

1.  Vancomycin: a history.

Authors:  Donald P Levine
Journal:  Clin Infect Dis       Date:  2006-01-01       Impact factor: 9.079

Review 2.  The pharmacokinetic and pharmacodynamic properties of vancomycin.

Authors:  Michael J Rybak
Journal:  Clin Infect Dis       Date:  2006-01-01       Impact factor: 9.079

Review 3.  Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists.

Authors:  Michael Rybak; Ben Lomaestro; John C Rotschafer; Robert Moellering; William Craig; Marianne Billeter; Joseph R Dalovisio; Donald P Levine
Journal:  Am J Health Syst Pharm       Date:  2009-01-01       Impact factor: 2.637

4.  A survey of beta-lactam antibiotics and vancomycin dosing strategies in intensive care units and general wards in Belgian hospitals.

Authors:  F M Buyle; J Decruyenaere; J De Waele; P M Tulkens; T Van Audenrode; P Depuydt; G Claeys; H Robays; D Vogelaers
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-12-28       Impact factor: 3.267

5.  Optimizing Vancomycin Use Through 2-Point AUC-Based Therapeutic Drug Monitoring in Pediatric Patients.

Authors:  Pintip Suchartlikitwong; Suvaporn Anugulruengkitt; Noppadol Wacharachaisurapol; Watsamon Jantarabenjakul; Jiratchaya Sophonphan; Tuangtip Theerawit; Tanittha Chatsuwan; Thitima Wattanavijitkul; Thanyawee Puthanakit
Journal:  J Clin Pharmacol       Date:  2019-07-24       Impact factor: 3.126

6.  Towards Rational Dosing Algorithms for Vancomycin in Neonates and Infants Based on Population Pharmacokinetic Modeling.

Authors:  Esther J H Janssen; Pyry A J Välitalo; Karel Allegaert; Roosmarijn F W de Cock; Sinno H P Simons; Catherine M T Sherwin; Johan W Mouton; Johannes N van den Anker; Catherijne A J Knibbe
Journal:  Antimicrob Agents Chemother       Date:  2015-12-07       Impact factor: 5.191

7.  Therapeutic Monitoring of Vancomycin for Serious Methicillin-resistant Staphylococcus aureus Infections: A Revised Consensus Guideline and Review by the American Society of Health-system Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists.

Authors:  Michael J Rybak; Jennifer Le; Thomas P Lodise; Donald P Levine; John S Bradley; Catherine Liu; Bruce A Mueller; Manjunath P Pai; Annie Wong-Beringer; John C Rotschafer; Keith A Rodvold; Holly D Maples; Benjamin Lomaestro
Journal:  Clin Infect Dis       Date:  2020-09-12       Impact factor: 9.079

Review 8.  Association between the AUC0-24/MIC Ratio of Vancomycin and Its Clinical Effectiveness: A Systematic Review and Meta-Analysis.

Authors:  Peng Men; Hui-Bo Li; Suo-Di Zhai; Rong-Sheng Zhao
Journal:  PLoS One       Date:  2016-01-05       Impact factor: 3.240

View more
  5 in total

Review 1.  [Therapeutic drug monitoring and pharmacokinetic models as a strategy for rational antibiotic therapy in intensive care patients].

Authors:  Lea Marie Schatz; Michael Zoller; Christina Scharf; Uwe Liebchen
Journal:  Anaesthesiologie       Date:  2022-06-15

2.  Therapeutic drug monitoring of vancomycin in neurosurgery patients, from trough concentration to area under the curve: a retrospective single center cohort study in a tertiary hospital.

Authors:  Yue Chen; Xudong Kong; Lei Liu
Journal:  J Int Med Res       Date:  2022-03       Impact factor: 1.671

3.  Systematic Comparison of Hospital-Wide Standard and Model-Based Therapeutic Drug Monitoring of Vancomycin in Adults.

Authors:  Heleen Gastmans; Erwin Dreesen; Sebastian G Wicha; Nada Dia; Ellen Spreuwers; Annabel Dompas; Karel Allegaert; Stefanie Desmet; Katrien Lagrou; Willy E Peetermans; Yves Debaveye; Isabel Spriet; Matthias Gijsen
Journal:  Pharmaceutics       Date:  2022-07-13       Impact factor: 6.525

4.  Continuous infusion versus intermittent infusion of vancomycin in critically ill patients undergoing continuous venovenous hemofiltration: a prospective interventional study.

Authors:  Jinhui Xu; Lufen Duan; Jiahui Li; Fang Chen; Xiaowen Xu; Jian Lu; Zhiwei Zhuang; Yifei Cao; Yunlong Yuan; Xin Liu; Jiantong Sun; Qin Zhou; Lu Shi; Lian Tang
Journal:  BMC Infect Dis       Date:  2022-08-02       Impact factor: 3.667

5.  Vancomycin therapeutic drug monitoring in patients on continuous renal replacement therapy: a retrospective study.

Authors:  Yuyan Liu; Li Jiang; Ran Lou; Meiping Wang; Quan Si
Journal:  J Int Med Res       Date:  2022-09       Impact factor: 1.573

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.